{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:45:39Z","timestamp":1764305139922},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T00:00:00Z","timestamp":1182902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11899-007-0022-2","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T04:42:55Z","timestamp":1182832975000},"page":"161-166","source":"Crossref","is-referenced-by-count":11,"title":["Is BEACOPP better than ABVD?"],"prefix":"10.1007","volume":"2","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,27]]},"reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","volume":"73","author":"V.T. DeVita Jr","year":"1970","unstructured":"DeVita VT Jr, Serpick AA: Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease. Ann Intern Med 1970, 73:881\u2013895.","journal-title":"Ann Intern Med"},{"key":"22_CR2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-92-5-587","volume":"92","author":"V.T. DeVita Jr","year":"1980","unstructured":"DeVita VT Jr, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin\u2019s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587\u2013595.","journal-title":"Ann Intern Med"},{"key":"22_CR3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.7326\/0003-4819-96-2-139","volume":"96","author":"A. Santoro","year":"1982","unstructured":"Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin\u2019s disease. Ann Intern Med 1982, 96:139\u2013143.","journal-title":"Ann Intern Med"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G. Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin\u2019s disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252\u2013259.","journal-title":"Cancer"},{"key":"22_CR5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJM198204013061303","volume":"306","author":"A. Santoro","year":"1982","unstructured":"Santoro A, Bonadonna G, Bonfante V, Valagussa P: Alternating drug combinations in the treatment of advanced Hodgkin\u2019s disease. N Engl J Med 1982, 306:770\u2013775.","journal-title":"N Engl J Med"},{"key":"22_CR6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"G.P. Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478\u20131484.","journal-title":"N Engl J Med"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-104-6-739","volume":"104","author":"G. Bonadonna","year":"1986","unstructured":"Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin\u2019s disease. Ann Intern Med 1986, 104:739\u2013746.","journal-title":"Ann Intern Med"},{"key":"22_CR8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.1985.3.9.1174","volume":"3","author":"P. Klimo","year":"1985","unstructured":"Klimo P, Connors JM: MOPP\/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin\u2019s disease. J Clin Oncol 1985, 3:1174\u20131182.","journal-title":"J Clin Oncol"},{"key":"22_CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.1998.16.1.19","volume":"16","author":"J.H. Glick","year":"1998","unstructured":"Glick JH, Young ML, Harrington D, et al.: MOPP\/ABV hybrid chemotherapy for advanced Hodgkin\u2019s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998, 16:19\u201326.","journal-title":"J Clin Oncol"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","volume":"21","author":"D.B. Duggan","year":"2003","unstructured":"Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607\u2013614.","journal-title":"J Clin Oncol"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1008294312741","volume":"8","author":"V. Diehl","year":"1997","unstructured":"Diehl V, Sieber M, R\u00fcffer U, et al.: BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin\u2019s disease. Ann Oncol 1997, 8:143\u2013148.","journal-title":"Ann Oncol"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood.V92.12.4560","volume":"92","author":"H. Tesch","year":"1998","unstructured":"Tesch H, Diehl V, Lathan B, et al.: Moderate dose escalation for advanced stage Hodgkin\u2019s disease using the bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin\u2019s Lymphoma Study Group. Blood 1998, 92:4560\u20134567.","journal-title":"Blood"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V. Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med 2003, 348:2386\u20132395.","journal-title":"N Engl J Med"},{"key":"22_CR14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/10428190500178167","volume":"46","author":"J.U. R\u00fcffer","year":"2005","unstructured":"R\u00fcffer JU, Ballova V, Glossman J, et al.: BEACOPP and COPP\/ABVD as salvage treatments after primary extended field radiation therapy of early stage Hodgkin\u2019s disease\u2014results of the German Hodgkin Study Group. Leuk Lymph 2005, 46:1561\u20131567.","journal-title":"Leuk Lymph"},{"key":"22_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","volume":"109","author":"E.J. Dann","year":"2007","unstructured":"Dann EJ, Bar-Shalom R, Tamir A, et al.: Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905\u2013909.","journal-title":"Blood"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","volume":"23","author":"K. Behringer","year":"2005","unstructured":"Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin\u2019s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 2005, 23:7555\u20137564.","journal-title":"J Clin Oncol"},{"key":"22_CR17","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","volume":"21","author":"A. Josting","year":"2003","unstructured":"Josting A, Wiedenmann S, Franklin J, et al.: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin\u2019s disease: a report from the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 2003, 21:3440\u20133446.","journal-title":"J Clin Oncol"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdh273","volume":"15","author":"K. Behringer","year":"2004","unstructured":"Behringer K, Josting A, Schiller P, et al.: Solid tumors in patients treated for Hodgkin\u2019s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004, 15:1079\u20131085.","journal-title":"Ann Oncol"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.2003.06.028","volume":"21","author":"M. Sieber","year":"2003","unstructured":"Sieber M, Bredenfield H, Josting A, et al.: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin\u2019s lymphoma: results of a pilot study of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 2003, 21:1734\u20131739.","journal-title":"J Clin Oncol"},{"key":"22_CR20","first-page":"546","volume":"91","author":"A. Engert","year":"2006","unstructured":"Engert A, Bredenfield H, D\u00f6hner H, et al.: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin\u2019s lymphoma: results of a phase II study. Haematologica 2006, 91:546\u2013549.","journal-title":"Haematologica"},{"issue":"pt1","key":"22_CR21","first-page":"33a","volume":"108","author":"A. Engert","year":"2006","unstructured":"Engert A, Franklin J, Mueller RP, et al.: HD12 randomized trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. Blood 2006, 108(pt 1):33a (Abstract 99).","journal-title":"Blood"},{"key":"22_CR22","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D. Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin\u2019s disease. N Engl J Med 1998, 339:1506\u20131514.","journal-title":"N Engl J Med"},{"key":"22_CR23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","volume":"16","author":"V. Ballova","year":"2005","unstructured":"Ballova V, R\u00fcffer J-U, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005, 16:124\u2013131.","journal-title":"Ann Oncol"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","volume":"14","author":"P. Hartmann","year":"2003","unstructured":"Hartmann P, Rehwald U, Salzberger B, et al.: BEACOPP therapeutic regimen for patients with Hodgkin\u2019s disease and HIV infection. Ann Oncol 2003, 14:1562\u20131569.","journal-title":"Ann Oncol"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1200\/JCO.2004.99.010","volume":"22","author":"G.P. Canellos","year":"2004","unstructured":"Canellos GP, Duggan D, Johnson J, Niedzwiecki D: How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004, 22:1532\u20131533.","journal-title":"J Clin Oncol"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"W.G. Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:7614\u20137620.","journal-title":"J Clin Oncol"},{"key":"22_CR27","first-page":"21a","volume":"16","author":"A. Santoro","year":"1997","unstructured":"Santoro A, Devizzi L, Bonfante V, et al.: Phase II study with gemcitabine in pretreated patients with Hodgkin\u2019s (HD) and non-Hodgkin\u2019s lymphomas (NHL): results of a multicenter study [abstract]. Proc Am Soc Clin Oncol 1997, 16:21a (Abstract 71).","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl1","key":"22_CR28","first-page":"339a","volume":"90","author":"H. Tesch","year":"1997","unstructured":"Tesch H, Santoro A, Fiedler F, et al.: Phase II study of gemcitabine in pretreated Hodgkin\u2019s disease: results of a multicenter study [abstract]. Blood 1997, 90(suppl 1):339a (Abstract 1514).","journal-title":"Blood"},{"key":"22_CR29","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1200\/JCO.2004.09.114","volume":"22","author":"H. Bredenfield","year":"2004","unstructured":"Bredenfield H, Franklin J, Nogova L, et al.: Severe pulmonary toxicity in patients with advanced-stage Hodgkin\u2019s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 2004, 22:2424\u20132429.","journal-title":"J Clin Oncol"},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.11582","volume":"98","author":"J.W. Friedberg","year":"2003","unstructured":"Friedberg JW, Neuberg D, Kim H, et al.: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin\u2019s disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978\u2013982.","journal-title":"Cancer"},{"key":"22_CR31","doi-asserted-by":"crossref","unstructured":"Bartlett N, Niedzwiecki D, Johnson J, et al.: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol 2007, In press.","DOI":"10.1093\/annonc\/mdm090"},{"key":"22_CR32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M. Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52\u201359.","journal-title":"Blood"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"B.D. Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579\u2013586.","journal-title":"J Clin Oncol"},{"key":"22_CR34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2005-12-5125","volume":"108","author":"A. Sanchez-Aguilera","year":"2006","unstructured":"Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108:662\u2013668.","journal-title":"Blood"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"816a","DOI":"10.1182\/blood.V106.11.816.816","volume":"106","author":"V. Diehl","year":"2005","unstructured":"Diehl V, Brillant C, Engert A, et al.: Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin\u2019s lymphoma [abstract]. Blood 2005, 106:816a.","journal-title":"Blood"},{"key":"22_CR36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000095559","volume":"73","author":"M. Fuchs","year":"2006","unstructured":"Fuchs M, Diehl V, Re D: Current strategies and new approaches in the treatment of Hodgkin\u2019s lymphoma [review]. Pathobiology 2006, 73:126\u2013140.","journal-title":"Pathobiology"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0022-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0022-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0022-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T17:58:58Z","timestamp":1587664738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0022-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,27]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0022-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,27]]}}}